The prognostic significance of delayed hypersensitivity to dinitrochlorobenzene and mechlorethamine hydrochloride in cutaneous T cell lymphoma

Journal of Investigative Dermatology

Volumn 110, Issue 6, 1998, Pages 946-950

  Vonderheid, Eric C ^a   Ekbote, Seema K ^a   Kerrigan, Kathleen ^a   Kalmanson, Jacob D ^c   Van Scott, Eugene J ^d   Rook, Alain H ^b   Abrams, J Todd ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Private Practice   (United States)

^d Private Practice of Dermatology   (United States)

Author keywords

T helper 2; T helper1

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; CHLORMETHINE; CYTOKINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CELLULAR IMMUNITY; CORRELATION FUNCTION; DELAYED HYPERSENSITIVITY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HELPER CELL; HUMAN; MAJOR CLINICAL STUDY; MALE; MYCOSIS FUNGOIDES; PRIORITY JOURNAL; SEZARY SYNDROME; SKIN ALLERGY; SKIN LYMPHOMA; SKIN SENSITIZATION; SKIN TEST; SURVIVAL RATE; T CELL LYMPHOMA;

EID: 0031809452     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.1998.00206.x     Document Type: Article

References (40)

1. Asadullah K, Döcke W-D, Haeußler A, Sterry W, Volk H-D: Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA. J Invest Dermatol 107:833-837, 1996
2. Berger CL, Wang N, Christensen I, Longley J, Heald P, Edelson RL: The immune response to class I-associated tumor-specific cutaneous T-cell lymphoma antigens. J Invest Dermatol 107:392-397, 1997
3. Blaylock WK, Clendenning WE, Carbone PP, Van Scott EJ: Normal immunologic reactivity in patients with the lymphoma mycosis fungoides. Cancer 19:233-236, 1966
4. Bleumink E, Nater JP, Koops HS, The TH: A standard method for DNCB sensitization testing in patients with neoplasms. Cancer 33:911-915, 1974
5. Bosworth JL, Ghossein NA, Brooks TL: Delayed hypersensitivity in patients treated by curative radiotherapy, its relationship to tumor response and short-term survival. Cancer 36:353-358, 1975
6. Bunu PA Jr, Lamberg SI: Report of the committee on staging and classification of cutaneous T-cell lymphomas. Cancer Treat Rep 63:725-728, 1979
7. Carter LL, Dutton RW: Type 1 and type 2: a fundamental dichotomy for all T-cell subsets. Curr Opin Immunol 8:336-342, 1996
8. Catalona WJ, Taylor PT, Chretien PB: Quantitative dinitrochlorobenzene contact sensitization in a normal population. Clin Exp Immunol 12:325-333, 1972a
9. Catalona WJ, Taylor PT, Taylor T, Rabson AS, Chretien PB: A method for dinitrochlorobenzene contact sensitization. N Engl J Med 286:399-402, 1972b
10. Cohen HA, Bekierkunst A: Treatment of mycosis fungoides with heat-killed BCG and cord factor. Dermatologica 158:104-116, 1979
11. D'Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, Trinchiere G: Interleukin 10 (IL-10) inhibits human lymphocyte interferon -production by suppressing natural killer cells stimulatory factor/interleukin-12 synthesis in accessory cells. J Exp Med 178:1041-1048, 1993
12. Diamandidou E, Cohen PR, Kurzrock R: Mycosis fungoides and Sézary syndrome. Blood 88:2385-2409, 1996
13. Dummer R, Heald PW, Nestle FO, Ludwig E, Laine E, Hemmi S, Burg G: Sézary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-receptor beta-chain). Blood 88:1383-1389, 1996
14. Eilber FR, Morton DL: Impaired immunologic reactivity and recurrence following cancer surgery. Cancer 25:363-367, 1970
15. Gajewski TF, Fitch FW: Anti-proliferative effect of IFN in immune regulation, I. IFN inhibits the proliferation of TH2 but not TH1 murine CTL clones. J Immunol 140:4245-4252, 1988
16. Gayá A, De la Calle O, Yague J, et al: IL-4 inhibits IL-2 synthesis and IL-2-induced upregulation of IL-2Rε but not IL-2Rβ chain in CD4+ human T cells. J Immunol 146:4209-4214, 1991
17. Hansen ER: Immunoregulatory events in the skin of patients with cutaneous T-cell lymphoma. Arch Dermatol 132:554-561, 1996
18. van der Harst-Oostveen CJGR, van Vloten WA: Delayed-type hypersensitivity in patients with mycosis fungoides. Dermatologia 157:129-135, 1978
19. Hazra TA, Parks LC, Inalsingh A, Peeples W: Delayed hypersensitivity to DNCB and survival following radiation therapy in patients with solid malignant tumors. Radiol 115:429-430, 1975
20. Hoppe RT, Medeiros LJ, Warnke RA, Wood GS: CD8-positive tumor infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides. J Am Acad Dermatol 32:448-453, 1995
21. Horikoshi T, Onodera H, Eguchi H, et al: A patient with plaque-stage mycosis fungoides has successfully been treated with long-term administration of IFN- and has been in complete remission for more than 6 years. Br J Dermatol 134:130-133, 1996
22. Kaplan EH, Rosen ST, Norris DB, Roenigk HH Jr, Saks SR, Bunn PA Jr: Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 82:208-212, 1990
23. Klein E, Holtermann O, Milgrom H, Case RW, Klein D, Rosner D, Djerassi I: Immunotherapy for accessible tumors utilizing delayed hypersensitivity reactions and separated components of the immune system. Med Clin NA 60:389-418, 1976
24. Kubba R, Bailin PL, Roenigk HH: Immunologic evaluation in mycosis fungoides. Arch Dermatol 116:178-181, 1980
25. Lee VT, Sparks FC, Eilber FR, Morton DL: Delayed cutaneous hypersensitivity and peripheral lymphocyte counts in patients with advanced cancer. Cancer 35:748-755, 1975
26. Marolleau JP, Baccard M, Flageul B, et al: High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma. Arch Dermatol 131:574-579, 1995
27. Mosmann TR, Sad S: The expanding universe of T cell subsets: Th1, Th2 and more. Immunol Today 17:138-146, 1996
28. Nordqvist BC, Kinney JP: Tand B cells and cell-mediated immunity in mycosis fungoides. Cancer 37:714-718, 1976
29. Parronchi P, DeCarli M, Manetti R, et al: IL-4 and IFN (α and γ) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones. J Immunol 149:2977-2983, 1992
30. Peleman R, Wu J, Rargeas C, Delespesse G: Recombinant interleukin 4 suppresses the production of interferon gamma by human mononuclear cells. J Exp Med 170:1751-1756, 1989
31. Pinsky CM, Wanebo H, Mike V, Oettgen H: Delayed hypersensitivity reactions and prognosis in patients with cancer. Ann NY Acad Sci 276:407-410, 1976
32. Ratner AC, Waldorf DS, Van Scott EJ: Alterations of lesions of mycosis fungoides lymphoma by direct imposition of delayed hypersensitivity reactions. Cancer 21:83-88, 1968
33. Romagnoli S, Parronchi P, D'Elios MM, et al: An update on human Th1 and Th2 cells. Int Arch Allergy Immunol 113:153-156, 1997
34. Rook AH, Heald P: The immunopathogenesis of cutaneous T-cell lymphoma. Hematol/ Oncol Clin NA 9:997-1010, 1995
35. Rook AH, Kubin M, Fox FE, et al: The potential therapeutic role of interleukin-12 in cutaneous T-cell lymphoma. Ann NY Acad Sci 795:310-318, 1996
36. Rybojad M, Marolleau JP, Flageul B, Baccard M, Brandely M, Morel P, Gisselbrecht C: Successful interleukin-2 therapy of advanced cutaneous T-cell lymphoma. Br J Dermatol 127:63-64, 1992
37. Vonderheid EC, Van Scott EJ, Johnson WC, Grekin DA, Asbell SO: Topical chemotherapy and immunotherapy of mycosis fungoides. Arch Dermatol 113:454-462, 1977
38. Vonderheid EC, Sobel EL, Nowell PC, Finan JB, Helfrich MK, Whipple DS: Diagnostic and prognostic significance of Sézary cells in peripheral blood smears from patients with cutaneous T-cell lymphoma. Blood 66:358-366, 1985
39. Vowels BR, Lessin SR, Cassin M, Jaworsky C, Benoit B, Wolfe JT, Rook AH: Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J Invest Dermatol 103:669-673, 1994
40. Wells SA Jr, Burdick JF, Joseph WL, Christiansen CL, Wolfe WG, Adkins PC: Delayed cutaneous hypersensitivity reactions to tumor cell antigens and to nonspecific antigens. J Thor Cardiovasc Surg 66:557-562, 1973